LAVA Therapeutics (LVTX) Proxy Filing summary

Executive summary

• The 2025 Annual General Meeting (AGM) is scheduled for June 11, 2025, in Utrecht, the Netherlands, with a record date of May 14, 2025, for voting eligibility.

• Shareholders can vote in person or by proxy, with instructions provided for various voting methods and deadlines.

• The proxy statement and annual report are available online, and the company encourages all shareholders to participate in voting.

Voting matters and shareholder proposals

• Proposals include adoption of 2024 Dutch statutory annual accounts, appointment and ratification of PricewaterhouseCoopers as external auditor for 2025, release of board members from liability for 2024, extension of board authorization to acquire shares, and reappointment of two non-executive directors.

• The board recommends voting FOR all proposals.

• Shareholder proposals for the 2026 AGM must be submitted by January 22, 2026, and comply with Dutch law and company articles.

Board of directors and corporate governance

• The board consists of eight members: one executive and seven non-executive directors, with staggered three-year terms.

• The chair is an independent non-executive director, and the board structure separates the roles of chair and CEO.

• All committees (Audit, Compensation, Nomination and Corporate Governance) are composed entirely of independent directors.

• The board conducts annual self-assessments and encourages director attendance at shareholder meetings.